他汀类药物与心力衰竭患者癌症风险及癌症相关死亡率降低相关
基于香港全港临床信息数据库的回顾性队列研究,纳入2003至2015年87 102例心衰患者,采用逆概率治疗加权平衡基线特征。中位随访4.1年,他汀使用与癌症发生率降低16%及癌症相关死亡率降低26%相关,且关联呈持续时间依赖性。
要点
- 心衰患者使用他汀与癌症发生风险降低16%独立相关(SHR=0.84)。
- 他汀使用与癌症相关死亡率降低26%相关(SHR=0.74)。
- 获益呈持续时间依赖性,使用≥6年者癌症风险降低更显著(SHR=0.78)。
核心结论
- 在心力衰竭患者中,他汀使用与癌症发生率及癌症相关死亡率显著降低相关,且该关联呈持续时间依赖性。
研究设计与样本
- 回顾性队列研究,使用全港临床信息数据库,纳入2003至2015年87 102例心衰患者。
- 他汀使用者36 176例,非使用者50 926例,采用逆概率治疗加权平衡基线协变量。
- 采用竞争风险回归与Cox比例风险模型估计癌症风险及癌症相关死亡率。
主要发现
- 中位随访4.1年(四分位距1.6-6.8年),11 052例(12.7%)被诊断为癌症。
- 他汀使用与癌症发生风险降低16%相关(多变量校正SHR=0.84;95%CI 0.80-0.89)。
- 与短期使用(3个月至<2年)相比,使用2至<4年SHR=0.99(95%CI 0.87-1.13),4至<6年SHR=0.82(95%CI 0.70-0.97),≥6年SHR=0.78(95%CI 0.65-0.93)。
- 他汀使用者10年癌症相关死亡率为3.8%,非使用者为5.2%(绝对风险差-1.4个百分点,95%CI -1.6%至-1.2%;校正SHR=0.74;95%CI 0.67-0.81)。
临床怎么用
- 对于心衰患者,长期使用他汀可能带来癌症风险及癌症相关死亡率降低的额外获益趋势。
- 临床决策中可结合患者个体情况考虑他汀使用的持续时间与潜在获益。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Patients with heart failure (HF) have an increased risk of incident cancer. Data relating to the association of statin use with cancer risk and cancer-related mortality among patients with HF are sparse. METHODS AND RESULTS: Using a previously validated territory-wide clinical information registry, statin use was ascertained among all eligible patients with HF (n = 87 102) from 2003 to 2015. Inverse probability of treatment weighting was used to balance baseline covariates between statin nonusers (n = 50 926) with statin users (n = 36 176). Competing risk regression with Cox proportional-hazard models was performed to estimate the risk of cancer and cancer-related mortality associated with statin use. Of all eligible subjects, the mean age was 76.5 ± 12.8 years, and 47.8% was male. Over a median follow-up of 4.1 years (interquartile range: 1.6-6.8), 11 052 (12.7%) were diagnosed with cancer. Statin use (vs. none) was associated with a 16% lower risk of cancer incidence [multivariable adjusted subdistribution hazard ratio (SHR) = 0.84; 95% confidence interval (CI), 0.80-0.89]. This inverse association with risk of cancer was duration dependent; as compared with short-term statin use (3 months to <2 years), the adjusted SHR was 0.99 (95% CI, 0.87-1.13) for 2 to <4 years of use, 0.82 (95% CI, 0.70-0.97) for 4 to <6 years of use, and 0.78 (95% CI, 0.65-0.93) for ≥6 years of use. Ten-year cancer-related mortality was 3.8% among statin users and 5.2% among nonusers (absolute risk difference, -1.4 percentage points [95% CI, -1.6% to -1.2%]; adjusted SHR = 0.74; 95% CI, 0.67-0.81). CONCLUSION: Our study suggests that statin use is associated with a significantly lower risk of incident cancer and cancer-related mortality in HF, an association that appears to be duration dependent.
引用
- Ren QW, Yu SY, Teng TK, et al. Statin associated lower cancer risk and related mortality in patients with heart failure. Eur Heart J. 2021. PMID: 34157723. doi:10.1093/eurheartj/ehab325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。